Publications

Manuscripts

  • Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor TT, Desideri S, Piantadosi S, Fisher JD, Fine HA: Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial for the NABTT CNS Consortium. JCO (in press 2009)
  • Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR, Jaeckel KA, Prados MD: Joint NCCTG and NABTC prognostic factors analysis for high grade recurrent glioma. Neuro-Oncology (in press 2009)
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen P, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A phase I trial of erlotinib in patients with non-progressive glioblastoma multiforme post radiation therapy, and recurrent malignant gliomas and meningiomas: A North American Brain Tumor Consortium Trial. Neuro-Oncology (in press 2009)
  • Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Robins IH, Junck L, Salazar AM, Chang SM: A North American Brain Tumor Consortium phase-2 study of poly-ICLC for adult patients with recurrent anaplastic glioma. J Neurooncol 91 (2): 183-189, 2009
  • Butowski N, Chang SM, Junck L, DeAngelis L, Abrey L, Fink K, Cloughesy T, Lamborn K, Salazar A, Prados MD: A North American Brain Tumor Consortium (NABTC 01-05) study of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma. J Neurooncol 91(2): 175-182, 2009
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A phase II trial of erlotinib in patients with recurrent malignant gliomas and non-progressive glioblastoma multiforme post radiation therapy: A North American Brain Tumor Consortium trial. Neuro-Oncology (in press)
  • Wen PW, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, De Angelis LM, Fine HA, Chang SM, Robins IH, Fink K, Abrey LE, Lassman AB, Mehta M, Drappatz J, Kesari S, Di Tomaso ED, Ligon K, Aldape K, Jain R, Capdeville R, Stiles C, Kaplan R, Ergin MJ, Murgo AT, Prados MD: Phase II study of imatinib mesylate (Gleevec®) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-Oncology March 17, 2009 [Epub ahead of print]
  • Phuphanich, S., Supko, JG., Carson, KA, Grossman, SA. Nabors, LB., Mikkelsen, T., Lesser, G., Rosenfeld, S., Desideri, S., Olson, J., Phase I Clinical Trial of Bortezomib in Adults with Recurrent Miligant Glioma.  J Neurooncol. 100:95-103.  2010 PMC3811025
  • Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR, Jaeckel KA, Prados MD: Joint NCCTG and NABTC prognostic factors analysis for high grade recurrent Glioma.  Neuro-Oncology. Feb; 12(2):164-72. 2010 PMC2940570
  • Holdhoff, M., Supko, JG,.Gallia, GL., Hann, CL., Bonekamk, D., Ye, X., Cao, B., Olivi, A., Grossman, SA., Intratumoral Concentrations of Imatinib after Oral Administration in Patients with Glioblastoma Multiforme.  J Neurooncol., Apr; 97 (2): 241-5, 2010 NIHMS497939 PMC 3927643
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen P, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A Phase I Trial of Erlotinib in Patients with Non-progressive Glioblastoma Multiforme Post Radiation Therapy, and Recurrent Malignant Gliomas and Meningiomas: A North American Brain Tumor Consortium Trial. Neuro-Oncology Jan; 12(1):95-103, 2010 PMC2940559
  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WKA, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, DeAngelis LM, Lieberman F, Cloughesy TF, Robins IH, Dancey J, Prados MD: A Phase II Trial of Erlotinib in Patients with Recurrent Malignant Gliomas and Non-progressive Glioblastoma Multiforme Post Radiation Therapy: A North American Brain Tumor Consortium Trial. Neuro-Oncol. Jan; 12(1): 95-103, 2010 PMC2940554
  • Grossman SA, Ye X, Piantadosi S, Nabors LB, Rosenfeld M, Fisher J. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States.  Clin Cancer Res. 15; 16:2443-9, 2010. PMC2861898
  • Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WKA, Gilbert MR, Fine HA, Mehta M, DeAngelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.  J of Neuro-Oncology 96 (2): 211-217, 2010 PMC 37861910
  • Rosenfeld MR, ChamberlainMC, Grossman SA, PeereboomDM, Lesser GJ, Batchelor TT, Desideri S, SalazarAM, YeX. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.  Neuro Oncol. 12:1071-7, 2010 PMC3018929
  • Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, DeAngelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II trial of pazopanib (GW786034), an oral multi-targeted antiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).  Neuro-Oncol 2010 March 3 [epub ahead of print] PMID 20200024 PMC2940686
  • Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA.  For the NABTT Consortium.  A Phase I/II trial and Pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gilomas. J Neuro Oncology Nov 100(2) 261-8 2010 PMC 3811044
  • Batchelor, T, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ, Rituximab monotherapy for patients with recurrent primary central nervous system lymphoma.  Neurology Mar 8; 76(10) 929-30 2011 PMC3059144
  • Rudek M, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, and Grossman SA for the New Approaches to Brain Tumor Therapy.  Neuro-Oncology 2011 May 6. [Epub ahead of print] PMC3197967
  • Nabors LB, Supko JG, Rosenfeld M Chamberlain M, Phupanich S, Batchelor T, Desideri S, Ye X, Wright J, Grossman SA. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.  Neuro Oncol, 13:1324-330, 2011. PMC3223097
  • Grossman SA, Ye X, Lesser G, Sloan A, Carraway, Desideri S, and Piantadosi S.  Immunosuppression in Patients with High Grade Gliomas Treated with Radiation and Temozolomide: A NABTT CNS Consortium Study.  Clin Cancer Res, 17:5473-80, 2011 PMC3156964
  • Clarke JL, Ennis MM, Yung WKA, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, and Prados MD: Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology 13 (10): 1118-1124, 2011 PMC3177665
  • de Groot JF, Lamborn KR, Chang S, Gilbert M, Cloughesy T, Aldape K, Yao J, Jackson E, Lieberman F, Robins IH, Mehta M, Lassman A, DeAngelis L, Yung WKA, Chen A, Prados M, and Wen P: Phase II study of Aflibercept (VEGF-TRAP) in recurrent malignant glioma: A North American Brain Tumor Consortium Study.  J Clin Oncol 29 (19): 2689-2695, 2011 PMC3139373
  • Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WKA, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA: A phase I/II trial of the histone deacetylase inhibitor, Romidepsis, for adults with recurrent malignant glioma (North American Brain Tumor Consortium Study 03-03.  Neuro-Oncology  13 (5): 509-516, 2011 PMC3093337
  • Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Iwanami A, Kazuhiro T, Gini B, DeJesus J, Lisiero D, Huang T, Prins R, Wen PY, Robbins IH, Prados MD, DeAngelis L, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS: An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.  Cancer Discov15;1 (5):442-456, 2011 PMC3207317
  • De Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach JV: Myeloid biomarkers associated with glioblastoma response to Anti-VEGF therapy with Afibercept.   Clinical Cancer Research 17 (14): 4872-4881, 2011 PMC3139700
  • Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF: A phase 1 trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys  81 (5): 1422-1427, Dec 2011 PMC3020272
  • Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S; Adult Brain Tumor Consortium. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012 pr;14(4):511-7. doi: 10.1093/neuonc/nor230. Epub 2012 Feb 8. PubMed PMID: 22323663; PubMed Central PMCID: PMC3309850
  • Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012 Nov 15;118(22):5601-7. doi: 10.1002/cncr.27585. Epub 2012 Apr PubMed PMID: 22517399; PubMed Central PMCID: PMC3423527
  • Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24. PubMed PMID: 23099651; PubMed Central PMCID: PMC3499017
  • Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, DeAngelis LM, Chang S, Prados M: Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neuro-Oncology, 106 (1): 147-153, 2012 PMC 4351869
  • Vivanco I, Robins HI, Rohle D, Camp[os C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A. Liau LM, Lieberman F. Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, Deangelis LM, Young WH, Kuhn JC, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK: Differential sensitivity of glioma versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.  Cancer Discovery 2 (5): 458-471, 2012 PMC3354723
  • Nayak, L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM and Omuro. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma A for the NABTC Consortium.  Leukemia & Lymphoma, 2013 Jan; 54(1):58-61; early online (NABTC 0501) PMC4779120
  • Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WKA, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern R, Xu J, Desideri S, Ye X, Ames M, Espinoza-Delgado I, Prados MD, Wen PY: Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: A North American Brain Tumor Consortium Study 04-03: Clin Cancer Res 2012, Aug 24 [Epub ahead of print] PMC 3947570
  • Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman A, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Jeymach J, deGroot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.  (NABTC 0601) Targeted Oncology 2013 June; 8(2):117-25 PMC4802008
  • David M. Peereboom; Manmeet S. Ahluwalia; Xiaobu Ye; Jeffrey G. Supko; Sarah L. Hilderbrand; Surasak Phuphanich; L. Burt Nabors; Myrna R. Rosenfeld; Tom Mikkelsen; Stuart A. Grossman; for the New Approaches to Brain Tumor Therapy (NABTT) Consortium NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme Neuro-Oncology 2013 Apr;15(4):490-6 PMC3607264
  • Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S,Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr;16(4):567-78 PMC 3956354
  • Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang C, Hu J, McAfee Q, Fisher J, Troxel A, Piao S, Heitian DF, Tan KS, Pontiggia L, O’Dwyer PJ, Davis LE, Amaravadi RK. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed Glioblastoma Multiforme. Autophagy 2014 Aug;10(8):1359-68  PMC 4203513
  • Gerstner ER., Ye X, Duda DG., Levine, MA. Mikkelsen T, Kaley TJ., Olson JJ., Nabors BL., Ahluwalia MS., Wen PY., Jain RK., Batchelor TT., Stuart Grossman. A Phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.  Neuro-Oncology 2015 Oct; 17(10):1386-92. PMC4578584
  • Blakeley JO., Grossman SA., Mikkelsen T, Rosenfeld MR., Peereboom D, Nabors BL., Chi AS Emmons G, Ribas IG, Supko JG., Desideri S and Ye X on behalf of the Adult Brain Tumor Consortium. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. J Neuro-Oncology 2015 Oct; 125(1): 123-3. PMC4869687
  • Streiff, M, Ye X, Kickler T, Desideri S, Jani J, Fisher J, Grossman SA. A prospective multicenter study of venous thromboembolism in patients with newly diagnosed high-grade glioma: hazard rate and risk factors. J Neuro-Oncology 2015 Sep: 124(2): 299-305. PMC4659392
  • Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients with Primary Central Nervous System Tumors, J Clin Onco 2015 Oct 1;33 (28):3186-92  PMC4857195
  • Kleinberg LR, Stieber V, Mikkelsen T, Judy K, Weingart J, Barnett G, Olson J, Desideri S, Ye X, Grossman SA. Outcome of Adult Brain Tumor Consortium (ABTC) Prospective Dose Finding Trials of I-125 Balloon Brachytherapy in High Grade Gliomas: Challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.  Journal of Radiation Oncology, in press 2015
  • PanE, SupkoJG, Kaley TJ., Butowski NA., Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park D. Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma 2016 submitted J Neuro-Oncology

 

Abstracts

 

  • Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld MR, Fisher J: Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the USA for the NABTT CNS Consortium, ASCO 2009
  • Fiveash JB, Chowdhary SA, Peereboom D, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA: NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM) for the NABTT CNS Consortium, ASCO 2009
  • Supko, JG, Grossman SA, Peereboom D, Chowdhary SA, Lesser GJ, Nabors LB, Mikkelsen T, Desideri S, Batchelor TT: Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. For the NABTT CNS Consortium, ASCO 2009
  • Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S: NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) for the NABTT CNS Consortium, ASCO 2009
  • Rosenfeld MR, Chamberlain M, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X: A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12 and 18 month survival data (NABTT 0501). For the NABTT CNS Consortium, ASCO 2009
  • Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Desideri S: Phase I Study of Teremeprecol in Patients with Recurrent High Grade Glioma for the NABTT CNS Consortium, WFNO-Asian Society 2009
  • Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, S Piantadosi, Fine H: Survival results from a multicenter phase II trial of Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. WFNO-Asian Society 2009
  • Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, DeAngelis L, Lieberman F, Lamborn K, Prados M: Interaction between sorafenib and erlotinib. J Clin Oncol 27: 15s, 2009
  • Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant glioma (NABTC 04-02). J Clin Oncol 27, 15s, 2009
  • Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol 27: 15s, 2009
  • Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M: Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (NABTC 05-02). J Clin Oncol 27: 15s, 2009
  • Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HI, Lassman A, Wen PY: Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (NABTC 05-02).J Clin Oncol 27: 15s, 2009
  • Piao Y, Heymach JV, Bekele B, Camphausen K, Wen PY, Liu J, Yung WK, De Groot J: Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol 27: 15s, 2009
  • Norden A, Raizer JJ, Lamborn KL, Abrey LE, Chang S, Gilbert MR, Cloughesy TF, Prados M, Lieberman F, Wen P: Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.  Neuro-Oncology 11 (5) 2009; page 622
  • Blakelely JO, Ye X, Grossman SA, Mikkelsen T, Rosenfeld MR, Bradley CR, Eichler AF, Nabors LB, Desideri, S, Supko JG, For the ABTC Consortium. Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolimide (TMZ) in malignant glioma.  J Clin Oncol 28:15s, 2010 (suppl; abstr 2012)
  • Grossman SA, Ye X, Lesser, GJ, Sloan AE, Carson C, Piantadosi S, For the NABTT CNS Consortium. Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS Consortium studyJ Clin Oncol 28:15s, 2010 (suppl; abstr 2013)
  • Rosenfeld MR, Grossman SA, Brem S, Mikkelsen T, Wang D, Piao S, Davis LE, O’Dwyer JP, Amaravadi RK. Pharmacokinetic analysis and pharmocodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603).  J Clin Oncol 28:15s, 2010 (suppl; abstr 3086)
  • Nayak L, Abrey L, Drappatz J, Gilbert M, Reardon D, Lamborn K, Wen P, Prados M, DeAngelis L, Omuro A, on behalf of the Adult Brain Tumor Consortium (ABTC). Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) Study 05-01 J Clin Oncol 29: 2011 (suppl; abstr 2039)
  • De Groot J. F., Cloughesy T., Lieberman F. S.,. Chang S. M, Omuro A. M. P., Drappatz J., Batchelor T., DeAngelis L. M., Gilbert M. R., Yung W. K. A., Fisher J. D., Ye X., Lamborn K., Chen A. P.,. Grossman S. A, Prados M., Wen P. Y. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly-diagnosed high-grade glioma. J Clin Oncol 29: 2011 (suppl; abstr 2043)
  • Wen P. Y., Puduvalli V. K., Kuhn J. G., Reid J. M., Lamborn K., Cloughesy T. F., Chang S. M., Drappatz J., Yung A W. K.., Gilbert M. R., Robins H. I., Lieberman F. S., Lassman A. B., McGovern R. M., Desideri S., Ye X., Ames M. M., Espinoza-Delgado I. J., Grossman S. A., Prados M. Phase 1 study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol 29: 2011 (suppl; abstr 2032)
  • Peereboom DM, Rich JN, Supko JG, Lamborn K, Ye X, Sloan AE, Prados M, Grossman SA. A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma  J Clin Oncol 29: 2011 (suppl; abstr TPS135)
  • Ye X, Grossman SA, Desideri S, Piantadosi S. Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM).  J Clin Oncol 29: 2011 (suppl; abstr 2008)
  • Sloan AE, Nock CJ, Kerstetter A, Supko J, Ye X, Barnholtz-Sloan J, Miller R, Rich J, Takebe N, Prados M, Grossman S. Targeting glioma stem cells (GSC): a biomarker and phase ii study of GDC-0449 in patients with recurrent glioblastoma multiforme. Neuro Oncol. 2012 Oct; 14(Suppl 6): vi101–vi105
  • Kleinberg LR, Blakeley J, Mikkelsen T, Stevens G, Ye X, Ryu S, Desideri S, Desai B, Giranda V, Grossman S. Phase 1 Trial of Veliparib (ABT-888), Temozolomide (TMZ), and Concurrent Radiation Therapy (RT) for Newly Diagnosed Glioblastoma Multiforme (GBM): Need for Modification to Approach for Combining These Therapies.  ASTRO 2012
  • Blakeley J, Fisher J, Lieberman F, Lupo J, Nabors B, Crane J, Wen YP, Cote A, Peere D, Wen Q, Cloughesy T, Robins HI, Desideri S, Grossman SA, Ye X, Nelson S. Imaging biomarkers of ramucirumab and olaratumab in patients with recurrent glioblastoma.  J Clin Oncol 31, 2013 (suppl; abstr 2044)
  • Holdhoff M, Grossman S, Supko J, Ye X, Fisher JD, Desideri S, Wahl RL, Schiff D. Sequential therapy with the selective t-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An adult brain tumor consortium phase 1 study (ABTC1101).  J Clin Oncol 31, 2013 (suppl; abstr TPS2105)
  • Gerstner ER, Levine M, Ye X, Mikkelsen T, Nabors B, Olson J, Kaley T, Wen PY, Batchelor TT, Grossman S. A Phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. J Clin Oncol 31, 2013 (suppl; abstr 2054)
  • Kleinberg LR, Mikkelsen T, Stevens G, Ye X, Desideri S, Ryu S, Desai B, Giranda V, Grossman S. Phase 1 Adult Brain Tumor Consortium (ABTC)Trial of ABT-888 (Veliparib), Temozolomide(TMZ), and Radiotherapy (RT) for Newly Diagnosed Glioblastoma Multiforme (GBM)  ASCO 2013 #2065
  • Nelson S, Lieberman F, Lupo J, Viziri S, Nabors L.B, Crane J, Wen Patrick, Andre Cote, Peereboom D, Wen Q, Cloughesy T, Robins H.I, Fisher J, Desideri S, Grossman S, Ye X, Blakeley J. Functional brain MRI for assessing early activity of ramucirumab and olaratumab in patients with recurrent glioblastoma SNO 2013 RA-041
  • Sloan AE, Nock C, Kerstetter A, Pink J, Rich J, Takebe N, Miller R, Prados P, Grossman S.  Targeting Glioma Stem Cells In GBM: A Phase 0/II Study Of Hedgehog Pathway Inhibitor GDC-0449.  Amer Assoc Neurological Surgeons. 2013
  • Sloan A, Targeting glioma initiating cells in GBM: ABTC-0904, a randomized phase 0/2 study targeting the sonic hedgehog-signaling pathway. J Clin Oncol 32:5s, 2014 (suppl; abstr 2026)
  • Holdhoff M,  Ye X, Nabors LB., Desai AS., Mikkelsen T, Lesser G, Read WL., Lieberman FS., Supko J, Fisher JD., Desideri S, Grossman SA., Schiff D, ABTC Investigators. Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase 1 Adult Brain Tumor Consortium study.  J Clin Oncol 33, 2015 (suppl; abstr 2033)
  • Holdhoff M., Lodge M., Bag A., Nabors L., Mintz A., Lesser G., Mankoff D., Desai A., Lieberman A., Leal J.,  Fisher J., Desideri S., Ye X., Grossman S., Schiff D., Wahl R. Results of exploratory 18F-FLT PET imaging in ten patients treated with the selective T-type calcium channel blocker mibefradil followed by temozolomide in the Adult Brain Tumor Consortium study ABTC 1101 SNO 2015
  • Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients with Primary Central Nervous System Tumors SNO 2015